Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5140971 | 0.82 | TSHR (0.42) | TSHRSMN1; SMN2MAPTKMT2AFAAH | |
| SCHEMBL1077999 | 0.77 | TSHR (0.45) | TSHRSMN1; SMN2MAPTKMT2AFAAH | |
| SCHEMBL45240 | 0.77 | TSHR (0.45) | TSHRSMN1; SMN2MAPTKMT2AFAAH | |
| SCHEMBL880051 | 0.77 | — | — | |
| SCHEMBL30285352 | 0.75 | TSHR (0.43) | TSHRSMN1; SMN2MAPTKMT2AFAAH | |
| Hydrochloric Acid SCHEMBL849719 | 0.75 | SMN1; SMN2 (0.54) | TSHRSMN1; SMN2MAPTKMT2AFAAH | |
| Dimethylamine SCHEMBL3953015 | 0.75 | TSHR (0.43) | TSHRSMN1; SMN2MAPTKMT2AFAAH | |
| SCHEMBL9047033 | 0.75 | ALOX15 (0.48) | TSHRSMN1; SMN2MAPTKMT2AFAAH | |
| SCHEMBL30961 | 0.75 | TSHR (0.43) | TSHRSMN1; SMN2MAPTKMT2AFAAH | |
| SCHEMBL7170680 | 0.75 | TSHR (0.43) | TSHRSMN1; SMN2MAPTKMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10912719-B2 | Personal care composition and method of making | THE PROCTER AND GAMBLE COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
| US-20160106663-A1 | PERSONAL CARE COMPOSITION AND METHOD OF MAKING | THE PROCTER & GAMBLE COMPANY | 2016-04-21 | — | — | US | disclosed |
| US-20160095809-A1 | METHOD OF IMPROVED VOLUME AND COMBABILITY USING PERSONAL CARE COMPOSITION COMPRISING A PRE-EMULSIFIED FORMULATION | THE PROCTER & GAMBLE COMPANY | 2016-04-07 | — | — | US | disclosed |
| US-20150368443-A1 | Stability of Zinc Pyrithione Dispersions | THE PROCTER & GAMBLE COMPANY | 2015-12-24 | — | — | US | disclosed |
| US-20140348886-A1 | Method of Achieving Improved Product Rheology, Cosmetic Consumer Acceptance and Deposition | THE PROCTER & GAMBLE COMPANY (US) | 2014-11-27 | — | — | US | disclosed |
| EP-2579972-A1 | METHOD FOR PREPARING A NON-IONIC SURFACTANT STABLE PERSONAL CARE DISPERSION | The Procter and Gamble Company (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20090087398-A1 | Method for Treating Damaged Hair | THE PROCTER & GAMBLE COMPANY | 2009-04-02 | — | — | US | disclosed |
| US-20080206355-A1 | Composition comprising a particulate zinc material, a pyrithione or a polyvalent metal salt of a pyrithione and a synthetic cationic polymer | THE PROCTER & GAMBLE COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-7288514-B2 | Polymer-fluorosurfactant associative complexes | THE CLOROX COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-20060234901-A1 | Polymer-fluorosurfactant associative complexes | CLOROX COMPANY, THE | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10912719-B2 | Personal care composition and method of making | CUTA, POLR1C, KRT18 | TSHR 2566/4885SMN1; SMN2 4129/4885MAPT 39/4885 |
| US-20080206355-A1 | Composition comprising a particulate zinc material, a pyrithione or a polyvalent metal salt of a pyrithione and a synthetic cationic polymer | SLC39A3, SLC39A14, SLC30A7 | TSHR 3015/4885SMN1; SMN2 3205/4885MAPT 1626/4885 |
| US-20160095809-A1 | METHOD OF IMPROVED VOLUME AND COMBABILITY USING PERSONAL CARE COMPOSITION COMPRISING A PRE-EMULSIFIED FORMULATION | POLR1C, SGMS1, CERT1 | TSHR 2928/4885SMN1; SMN2 1024/4885MAPT 2272/4885 |
| US-20090087398-A1 | Method for Treating Damaged Hair | LPO, MAG, CUTA | TSHR 2299/4885SMN1; SMN2 4423/4885MAPT 2355/4885 |
| US-20140348886-A1 | Method of Achieving Improved Product Rheology, Cosmetic Consumer Acceptance and Deposition | POLR1C, PIK3C3, CUTA | TSHR 2206/4885SMN1; SMN2 1922/4885MAPT 1495/4885 |
| US-20160106663-A1 | PERSONAL CARE COMPOSITION AND METHOD OF MAKING | CUTA, POLR1C, KRT18 | TSHR 2566/4885SMN1; SMN2 4129/4885MAPT 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.